Danaher Corporation (NYSE:DHR) saw its stock tumble 7% intra-day today after reporting mixed fourth-quarter results. While revenue exceeded expectations, earnings came in slightly below forecasts, leaving investors cautious about the company’s outlook.
The life sciences and diagnostics giant posted adjusted earnings per share of $2.14, just below the projected $2.15. Revenue, however, rose to $6.54 billion, surpassing the consensus estimate of $6.39 billion and reflecting a 2% year-over-year increase. Non-GAAP core revenue edged up 1% compared to the same period last year.
Despite the revenue beat, investor sentiment remained lukewarm due to concerns over forward guidance. For the first quarter of 2025, Danaher anticipates a low-single-digit decline in non-GAAP core revenue year-over-year. However, for the full year, the company expects approximately 3% non-GAAP core revenue growth.
In 2024, Danaher reported total revenue of $23.9 billion, flat compared to the previous year, with non-GAAP core revenue declining 1.5%. Operating cash flow reached $6.7 billion, while non-GAAP free cash flow totaled $5.3 billion.